Abstract:Autoimmune disease refers to a kind of chronic systemic disease in which the body is mistakenly attacked by the immune system, causing damages to cells, tissues and organs. Studies show that the incidence of autoimmune diseases now accounts for 7%-9% of the global population, and is increasing year by year. Current methods for the treatment of autoimmune diseases (such as immunosuppressant and plasma exchange) lack sufficient safety and effectiveness. Therefore, it is necessary to develop new treatment methods. Immunoadsorption (IA) is a method of selective or nonselective removal of autopathogenic antibodies to achieve the therapeutic effect on autoimmune diseases. Immunosorbent therapy can effectively avoid various side effects such as fever, nausea and infection caused by current treatment, and quickly improve the degree of disease in a short time. At present, the vast majority of IA columns in clinical application are nonselective adsorption, which may deplete the whole immunoglobulin spectrum and lead to serious adverse reactions and autoantibody rebound. Selective immunoadsorption can specifically remove pathogenic antibodies without immunoglobulin replacement, and the adsorption efficiency is higher. Thus, selective immunoadsorption is a better treatment option, but long-term research shows that the development of its adsorbent is also more difficult. However, with the in-depth study of the pathological mechanism of autoimmune diseases and the rapid development of biomedical engineering, more and more potential targets of in vitro immunoadsorption have been identified, and the research of selective immunoadsorption has entered a stage of rapid development. This paper introduces the research and clinical application of immunoadsorption in four autoimnume diseases: dilated cardiomyopathy (DCM), idiopathic membranous nephropathy (IMN), systemic lupus erythematosus (SLE) and myasthenia gravis (MG), discusses the effectiveness and safety of this treatment method, and emphasizes the need to strengthen the study on the treatment of selective immunoadsorption to remove pathogenic antibodies. At the same time, it is pointed out that in order to realize the clinical application of immunoadsorption in more diseases, more in-depth preclinical trials need to be done in terms of reliability, regionality and sample size.

Main biologics for anti-autoimmune disease:research advances

Research Development in Treating Autoimmune Diseases by Biological Methods

Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders

An updated advance of autoantibodies in autoimmune diseases

Research Progress of Immunoadsorption in The Treatment of Autoimmune Diseases: a Review

Small Molecule Approaches to Treat Autoimmune and Inflammatory Diseases (part I): Kinase Inhibitors.

New insight in treating autoimmune diseases by targeting autophagy

The role of inflammation in autoimmune disease: a therapeutic target

Autoantibodies - enemies, and/or potential allies?

The Molecular Basis Of Immune Regulation In Autoimmunity

[Advances of using antibody against B cell activating factor for treatment of autoimmune diseases].

Recent Advances in Cell Therapeutics for Systemic Autoimmune Diseases

[Biologics for Targeting Inflammatory Cytokines and Their Clinical Application].

[Research Advances of Autoimmune Liver Diseases in 2018].

Breaking barriers: advancing cellular therapies in autoimmune disease management

Recent advances of nanotechnology application in autoimmune diseases – A bibliometric analysis

Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date

The Progress of Pathogenesis of Autoimmune Diseases

Low-dimensional nanomaterials enabled autoimmune disease treatments: Recent advances, strategies, and future challenges

The Anti-Inflammatory and Immunomodulatory Activities of Natural Products to Control Autoimmune Inflammation

Research advances in the role and pharmaceuticals of ATP-binding cassette transporters in autoimmune diseases